Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bictegravir/emtricitabine/tenofovir alafenamide - Gilead Sciences

Drug Profile

Bictegravir/emtricitabine/tenofovir alafenamide - Gilead Sciences

Alternative Names: B/F/TAF; BIC/FTC/TAF; Bictegravir/F/TAF; Bictegravir/tenofovir-alafenamide/emtricitabine; Biktarvy; Emtricitabine/bictegravir/tenfovir-alafenamide; Emtricitabine/GS 9883/tenofovir alafenamide; Emtricitabine/tenofovir-alafenamide/GS-9883; Emtricitabine/tenofovir-alafenamine/bictegravir; F/GS 9883/TAF; GS 9883/F/TAF; GS 9883/tenofovir alafenamide/emtricitabine; GS-9883/emtricitabine/tenofovir alafenamide; J05AR20; Tenofovir-alafenamide/bictegravir/emtricitabine; Tenofovir-alafenamide/emtricitabine/bictegravir; Tenofovir-alafenamide/emtricitabine/GS-9883; Tenofovir-alafenamide/GS-9338/emtricitabine

Latest Information Update: 28 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences
  • Class Antiretrovirals; Deoxyribonucleosides; Oxazepines; Purines; Pyrazines; Pyridones; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action DNA polymerase beta inhibitors; DNA polymerase gamma inhibitors; DNA polymerase I inhibitors; DNA polymerase II inhibitors; HIV integrase inhibitors; HIV reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV-1 infections
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV-1 infections
  • Phase III Hepatitis B

Most Recent Events

  • 15 Mar 2024 Gilead Sciences completes a phase III trial in Hepatitis B and HIV-1 infections (Treatment-naïve) in USA, Puerto Rico, France, Spain, Greece, China, Dominican Republic, Hong Kong, Japan, South Korea, Malaysia, Singapore, Taiwan, Thailand, Turkey (NCT03547908) (EudraCT2018-000926-79)
  • 07 Mar 2024 Updated adverse events data from a phase III Alliance trial in HIV-1 infections and Hepatitis B released by Gilead Sciences
  • 26 Feb 2024 US FDA approves Bictegravir for HIV 1 infection with suppressed viral loads, pre-existing resistance
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top